IRulya Therapeutics QNCX
NASDAQ QNCX
$32.83 -1.85 (-5.33%)
At close: Oct 22, 2026 · 4:00 PM EDT

Quince Therapeutics (QNCX) Gains from Sales and Divestitures (2022 - 2023)

Updated

IRulya Therapeutics (QNCX) posted Gains from Sales and Divestitures of $34,000 for Q4 2023, compared with -$17,000 a year earlier and up 325.0% from the prior quarter.

Analysis

Quince Therapeutics (QNCX) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends

For FY2023, IRulya Therapeutics' Gains from Sales and Divestitures came in at -$37,000.

  • In prior years, IRulya Therapeutics' Gains from Sales and Divestitures was -$94,000 in FY2022.
  • According to Business Quant data, Gains from Sales and Divestitures for the three prior quarters was $8,000 (Q3 2023), -$6,000 (Q2 2023) and -$73,000 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 IRulya Therapeutics 201.34 Mn 229.15 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 34,000.00
Sep 30, 2023 8,000.00
Jun 30, 2023 -6,000.00
Mar 31, 2023 -73,000.00
Dec 31, 2022 -17,000.00
Jun 30, 2022 -77,000.00
API Access

Quince Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=QNCX&period=max&api_key=YOUR_API_KEY